US 11,918,630 B2
Treatment of retina and nerve using laminin
Noriko Koizumi, Kyotanabe (JP); Naoki Okumura, Kyotanabe (JP); and Shigeru Kinoshita, Kyoto (JP)
Assigned to KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, Kyoto (JP); THE DOSHISHA, Kyoto (JP); and SENJU PHARMACEUTICAL CO., LTD., Osaka (JP)
Appl. No. 15/523,282
Filed by KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, Kyoto (JP); THE DOSHISHA, Kyoto (JP); and SENJU PHARMACEUTICAL CO., LTD., Osaka (JP)
PCT Filed Oct. 30, 2015, PCT No. PCT/JP2015/005474
§ 371(c)(1), (2) Date Apr. 28, 2017,
PCT Pub. No. WO2016/067629, PCT Pub. Date May 6, 2016.
Claims priority of application No. 2014-222948 (JP), filed on Oct. 31, 2014.
Prior Publication US 2017/0319665 A1, Nov. 9, 2017
Int. Cl. A61K 38/39 (2006.01); A61K 9/00 (2006.01); A61K 31/4409 (2006.01); A61K 35/30 (2015.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 27/02 (2006.01)
CPC A61K 38/39 (2013.01) [A61K 9/0048 (2013.01); A61K 31/4409 (2013.01); A61K 35/30 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); A61P 27/02 (2018.01)] 3 Claims
 
1. A method for treating a disease, a disorder, or a condition of a nerve requiring cell transplantation in a subject, comprising administering (a) at least one agent selected from the group consisting of laminin 511 (α5β1γ1) and fragments thereof and (b) a nerve cell or a retinal pigment epithelial cell to the subject, wherein the disease, the disorder, or the condition of the nerve requiring cell transplantation in the subject includes retinitis pigmentosa, macular degeneration, Stargardt disease, glaucoma, or optic neuropathy.